EPIX Medical, Inc.

	Nasdaq: EPIX	Change symbol:

PROFILE EPIX Medical wants to give you that special glow. The development-stage company makes contrast agents which boost the effectiveness of magnetic resonance imaging (MRI) by enhancing the visibility of arteries and veins. Its main product, AngioMARK (MS-325), is an injectable agent for use in diagnosing vascular diseases, including coronary artery disease and peripheral vascular disease. The company is also testing MS-325 for use in breast cancer detection. EPIX has formed alliances with several firms, including Mallinckrodt and Schering AG, to develop and commercialize its contrast agents. Other products in development include contrast agents for detecting blood clots and locating tumors.  COMPETITION Amersham plc (NYE) Guerbet Group (GBT)		STOCK ANALYSIS  View by:  Day   Day   Month   Month   Year   Year  FURTHER ANALYSIS • Advanced Charting • Deals  FINANCIAL OVERVIEW Fiscal Year-End: December 2000 Sales (mil.): 6.90 1-Yr. Sales Growth: 527.3% Employees: 83 Revenue per employee: $83,132.53  KEY PEOPLE • Michael D. Webb     CEO • Pamela E. Carey     CFO  CONTACT INFO 71 Rogers St. Cambridge, MA 02142 US Phone: 617-250-6000 Fax: 617-250-6031 Online: Web Site

	Company Data   News, quotes & more

		Hoover's Company Capsule Copyright © 2001, Hoover's Inc. Austin, Texas. For changes and updates, contact Hoover's directly.